Plastic Surgery Doctors in Duluth, MN Accepting Medicare

7 Plastic Surgery doctors found. Showing 1 - 7

Dr. Sarah Layne Crandall, M.D., Plastic Surgery Medicare: Medicare Enrolled Practice Location: 1420 London Rd Ste 101, Duluth, MN 55805 Phone: 218-724-7363

Dr. Edgar F. Saldana, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 324 W Superior St Ste 100, Duluth, MN 55802 Phone: 218-215-8990    Fax: 218-217-4371

Dr. Andrew Baertsch, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1420 London Rd, Suite 101, Duluth, MN 55805 Phone: 218-724-7363    Fax: 218-724-6199

Andrew Daniel Messa, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1420 London Rd, Suite 101, Duluth, MN 55805 Phone: 218-724-7363    Fax: 218-724-6199

Dr. Wade Daniel Kubat, D.O. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1012 E 2nd St, Duluth, MN 55805 Phone: 218-249-7910    Fax: 218-249-7999

Mr. Thomas Jon Rishavy, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1420 London Rd, Suite 101, Duluth, MN 55805 Phone: 218-724-7363    Fax: 218-724-6199

Dean Herbert Weber, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1420 London Rd, Suite 101, Duluth, MN 55805 Phone: 218-724-7363    Fax: 218-724-6199

News Archive

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

Even when HIV prevention drug is covered, other costs block treatment

Three years ago, Corey Walsh, who was in a relationship with a man who was HIV-positive, got a prescription for Truvada, a drug approved by the Food and Drug Administration to prevent infection with the virus that causes AIDS.

Researchers propose consumers buy yearly 'drug licenses' as new way to pay for prescriptions

Changing the way consumers pay for prescription drugs so that the system more closely resembles paying for cell phones or computer software could increase drug use without altering patients' out-of-pocket spending, health plan costs or drug company profits, according to a new RAND Corporation study.

Read more Medical News

› Verified 3 days ago